52601-82-8

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 16695-22-0 N,N-bis(tosyloxyethyl)-p-toluenesulfonamide 
• 70-55-3 toluene-4-sulfonamide 
• 247129-85-7 (2-bromoethyl)(diphenyl)sulfonium trifluoromethanesulfonate 

Downstream Products

• 1523618-34-9 [1-(4-methylbenzene-1-sulfonyl)piperidine-4,4-diyl]dimethanol 
• 100239-86-9 1-mesityl-4-tosylpiperazine 
• 1384448-13-8 C₂₀H₂₄N₂O₂S 
• 1384448-06-9 C₂₀H₂₅FN₂O₂S 
• 897017-12-8 N,N'-bistosyl-1,7-dithia-4,11-diazacyclotetradecane 

Relevant academic research and scientific papers

Pyruvate kinase activators for use in therapy

Described herein are methods for using compounds that activate pyruvate kinase.

Iron-catalyzed oxidative C(3)-H functionalization of amines

Fe-catalyzed direct dehydrogenative C(3)-functionalization of tertiary arylamines was developed via activation of the sp3 C(3)-H bond. The reaction is applicable to both cyclic and acyclic amines. The key process is the catalytic desaturative enamine formation from tertiary amines and position-selective C-C bond formation (addition to nitro olefins) at the β-carbon. Products can be converted to versatile and unique nitrogen-containing molecules.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.

The synthesis and characterization of the pendant-armed ligand N,N′-bis(2′-pyridylmethyl)-1,7-dithia-4,11-diazacyclotetradecane (L4) and crystal structures of L4 and the copper(II) complex [Cu(L4)](ClO4)2

The synthesis and characterization of the mixed donor ligand N,N′-bis(2′-pyridylmethyl)-1,7-dithia-4,11-diazacyclotetradecane (L4) containing two pendant pyridine arms is described. The macrocycle formation involves reaction of N-tosylbis(2-bro

INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention can provide a cancer treatment drug containing, as an active ingredient, a substance selected from the group consisting of an indazole compound of the following formula (I), a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate:

A new method for the preparation of nitrogen-containingheterocycles using diphenylsulfonium triflates

Various nitrogen heterocycles were produced by the reactions of ω-bromoalkyldiphenylsulfonium or diphenylsyylsulfonium triflates with nitrogen nucleophiles. Further, the reactions of diphenylstyrylsulfonium triflates with N-metalated phthalimide and imida

Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl]piperazine

Levorotatory and dextrorotatory enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl)sulfonyl]piperazine of the formula STR1 their preparation and use for the preparation of substantially optically pure enantiomers of 1-[(4-chlorophenyl)phenylmethyl]piperazine, which are themselves valuable intermediate products for the preparation of optically active therapeutic compounds having a very high degree of optical purity.